Acadia Pharmaceuticals' ACP-104 for treatment of Schizophrenia safe and well tolerated, study shows

By Angela McDaniels

Seattle, Nov. 10 - Acadia Pharmaceuticals Inc. said initial results from an ongoing clinical trial of ACP-104 in patients with schizophrenia show the drug to be safe and well tolerated.

ACP-104 is being evaluated in three clinical trials in collaboration with Carol Tamminga of the University of Texas Southwestern Medical School in Dallas.

The first trial compared the safety and tolerability of single, ascending doses of ACP-104 in 10 patients with schizophrenia compared to placebo.

Because the doses tested to date have been well tolerated, Acadia said it will expand the single ascending-dose study to test higher-than-expected doses of ACP-104.

The other two trials are studying the safety and efficacy of multiple ascending doses of ACP-104 and the correlation between brain receptor occupancy and plasma levels of ACP-104.

The company expects to report complete results from all three trials during the first half of 2006.

San Diego, Calif.-based Acadia Pharmaceuticals develops treatments for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.